Diabetes Treatment in China: What Works, What’s Experimental & Who Should Travel
China can be relevant for complex endocrinology, diabetes complications, metabolic care, specialist second opinions and selected clinical-research routes. Routine Type 1 and Type 2 treatment still follows the same evidence-based principles used internationally; the main differences are access to particular Chinese hospitals, China-specific medicines and an active regenerative-medicine research pipeline.
Short answer: China does not have a routine universal cure for diabetes. Type 1 diabetes still
requires insulin-based treatment for most patients. Some people with Type 2 diabetes can achieve
remission, but remission is not the same as a permanent cure. China has produced important
stem-cell-derived islet research, yet published results and registered trials are not the same as a treatment that
every overseas patient can book.
✓ Standard care separated from research
✓ Hospital fit separated from trial access
✓ No cure guarantee
✓ Travel only after a realistic route is confirmed
Standard Diabetes Care, Research, or a Clinical Trial?
Not every “new diabetes treatment in China” means the same thing. Before comparing hospitals, prices or travel, separate the route into established diabetes care, research or experimental options that need evidence verification, or a registered clinical trial with study-specific screening.
Standard diabetes treatment
Use this route for specialist endocrinology, difficult glucose control, diabetes complications, metabolic care, second opinions and other established clinical services.
Verify the evidence before treating an offer as a treatment route
A published paper, hospital research program and commercial package are not interchangeable. Verify the exact intervention, evidence, provider and current access before planning travel or payment.
Recruiting does not mean eligible or enrolled
Every trial has its own protocol, sites, recruitment status and eligibility criteria. The study team makes the screening and enrollment decision.
What records should an international diabetes patient prepare?
Start with: 1) diabetes type or classification if known; 2) a recent HbA1c; 3) current medicines, insulin regimen
or device; 4) records for the complication or treatment question; and 5) a concise treatment history. These records
improve routing readiness but do not determine diagnosis, hospital acceptance or trial eligibility.
For more detail, see the full medical-record checklist below.
This is a records-readiness and routing step, not a diagnosis, treatment recommendation, hospital-acceptance decision or clinical-trial eligibility decision.
Diabetes Treatment in China: At a Glance
Routine diabetes treatment is not a special “China cure”
Insulin, continuous glucose monitoring, automated insulin delivery, individualized Type 2 medication, weight management and complication screening remain the foundation of care.
Dorzagliatin is an approved Type 2 diabetes medicine in China
Dorzagliatin is a glucokinase activator approved in China for adults with Type 2 diabetes, including use as monotherapy or with metformin. It is a glucose-lowering medicine, not a cure.
Tzield is approved in China for stage 2 Type 1 diabetes
China’s NMPA approved teplizumab (Tzield) for adults and children aged 8 years and older with stage 2 autoimmune Type 1 diabetes to delay progression to stage 3 disease. It is not a treatment for established stage 3 Type 1 diabetes and does not replace insulin in people who already need it.
Stem-cell-derived islet results are scientifically important but still experimental
Chinese teams have reported early Type 1 and Type 2 islet-replacement results, including 2024 first-in-human reports and a 2026 Type 1 report involving three recipients. These findings do not establish routine availability.
Evidence, hospital care and trial access are three separate questions
A treatment can be scientifically credible without being commercially available, and a recruiting trial can exist without accepting an overseas patient. The receiving hospital or investigator must confirm the actual route.
Medical evidence reviewed: 20 September 2026. Routing and citation-ready decision layer updated: 24 September 2026.
Choose the Right Diabetes Path in China
These pages answer different patient questions. Start with the one that matches your actual reason for considering China.
Type 1 diabetes
Type 1 Diabetes Treatment in China
Insulin, CGM and automated insulin delivery, difficult cases, islet replacement, trial eligibility and current research.
TYPE 1 PATH →
Type 2 diabetes
Type 2 Diabetes Treatment in China
Remission, weight and metabolic treatment, complications, metabolic surgery and experimental research.
TYPE 2 PATH →
Cell therapy
Stem Cell Therapy for Diabetes in China
Published evidence, islet-cell research, mesenchymal-cell studies, commercial packages and red flags.
STEM-CELL EVIDENCE →
Clinical research
Diabetes Clinical Trials in China
Current trial IDs, interventions, hospitals, recruitment-status freshness, basic eligibility and foreign-patient access.
TRIAL TRACKER →
Hospital selection
Best Diabetes Hospitals in China
Compare PUMCH, Ruijin, West China, Second Xiangya and Tianjin First Center by case fit and international access.
HOSPITAL SHORTLIST →
Cost
Diabetes Treatment Cost in China
Official public price examples, routine care vs experimental treatment, international-patient costs and hospital-specific quotes.
COST GUIDE →
Type 1 vs Type 2: Why the China Path Is Different
| Type 1 diabetes | Type 2 diabetes | |
|---|---|---|
| Core problem | Autoimmune destruction of insulin-producing beta cells causes severe insulin deficiency. | Insulin resistance plus progressive beta-cell dysfunction, often associated with excess weight and metabolic disease. |
| Standard treatment | Insulin replacement, CGM, education and often pump/AID technology. | Individualized medication, weight management, cardiovascular/kidney risk treatment and insulin when required. |
| Can remission occur? | Routine insulin-free remission is not established as standard care. | Yes, some patients can achieve remission, especially after substantial sustained weight loss or metabolic surgery. |
| China research angle | Stem-cell-derived islets, beta-cell replacement and experimental immune approaches. | Remission-focused regimens, new drugs, procedures and cell-therapy studies. |
| When travel may make sense | Difficult control, severe hypoglycemia, complications, tertiary second opinion or a specific trial inquiry. | Complex metabolic disease, serious complications, surgery evaluation, specialist second opinion or a specific study. |
What the China Diabetes “Cure” Headlines Actually Mean
The research is real; a universal cure claim is not. Search results increasingly mix peer-reviewed
cell-therapy papers, approved medicines, preclinical synthetic-biology work and commercial medical-tourism offers.
They should not be treated as equivalent levels of evidence or availability. Chinese teams have published several important
regenerative-medicine results: a 2024 Type 1 diabetes first-in-human report using autologous chemically induced
pluripotent-stem-cell-derived islets, a 2024 Type 2 diabetes case using stem-cell-derived islet tissue, and a 2026
Lancet Diabetes & Endocrinology report describing autologous and allogeneic stem-cell-derived islet
therapy in three Type 1 diabetes recipients. These are early, highly selected research experiences — not evidence
that every patient can buy the same protocol.
What happened in a defined study
A peer-reviewed paper can establish the protocol, patient population, follow-up and observed outcome. It does not by itself prove routine availability, long-term durability or suitability for another patient.
A protocol that may be recruiting
Eligibility, study site and registry status can be checked publicly, but the investigator still decides whether a patient qualifies and whether an overseas patient can be screened.
GIFT “smart probiotic” is research, not a patient treatment route
East China Normal University researchers reported an engineered glucose-sensing probiotic designed to respond to glucose changes and secrete glucose-lowering hormones. The 2026 work is an important synthetic-biology signal, but it should not be presented as a clinic-ready capsule or yogurt treatment for international patients.
A treatment sold for cash
A self-pay “stem-cell diabetes package” is not automatically the same cell product, dose, manufacturing process or protocol used in a published paper or registered clinical study.
For current study IDs, sites and recruitment-status checks, use the Diabetes Clinical Trials in China tracker. For the evidence-vs-offer distinction, see Stem Cell Therapy for Diabetes in China.
Which Diabetes Hospitals in China Should International Patients Consider?
There is no universal #1 hospital. The best centre depends on whether the patient needs complex endocrinology, metabolic care, diabetic-foot treatment, diabetes classification or a specific experimental protocol.
PUMCH / West China Hospital
Large tertiary hospitals can be logical routes when diabetes is combined with kidney, cardiovascular, vascular, wound or other serious complications. Their international-patient pathways must still be confirmed case by case.
Ruijin / Second Xiangya / the exact trial site
For difficult metabolic disease, classification questions or experimental treatment, the relevant specialty center or registered study site can matter more than a hospital’s overall reputation.
Beijing Ruijing Diabetes Hospital
The International Diabetes Federation lists Beijing Ruijing Diabetes Hospital as a Centre of Excellence focused on Type 1 and Type 2 diabetes, diabetic foot, retinopathy, neuropathy and long-term diabetes management. That recognition does not by itself confirm an international-patient route, English-language care or a specific treatment offer.
See the full comparison, including international-access labels: Best Diabetes Hospitals in China for International Patients.
How Much Does Diabetes Treatment in China Cost?
There is no single national diabetes-treatment package price. A routine endocrine consultation and
laboratory work-up are completely different from inpatient complication treatment, metabolic surgery or
experimental cell-therapy screening.
How to get a current treatment estimate:
use a records-first route:
medical records → provider review → treatment route → current estimate → patient decision.
Keep medical charges separate from travel, hotel and translation. A price should be published or relied on only when
it comes from a current primary source or a current case-specific provider estimate with a verification date.
For an international patient, the useful number is a hospital-specific estimate after records review. Public Chinese medical price schedules can provide reference points for individual tests, but they should not be converted into a fake medical-tourism package or treated as a guaranteed case price.
See our full breakdown: Diabetes Treatment Cost in China.
When Does Travelling to China for Diabetes Treatment Make Sense?
A defined problem that needs a specific centre
- Difficult Type 1 or Type 2 control despite documented treatment
- Repeated severe hypoglycemia
- Major kidney, cardiovascular or diabetic-foot complications
- Complex obesity/metabolic disease or surgery evaluation
- A specialist second opinion at a named tertiary hospital
- A specific registered clinical trial you want screened
A generic “China cure” promise
- Routine medication refill or simple HbA1c follow-up
- A clinic that cannot name the exact protocol
- A treatment sold identically for Type 1 and Type 2
- A guaranteed insulin-free result before medical review
- Paying before anyone examines HbA1c, C-peptide or complications
- Booking flights before hospital or study-team confirmation
What Medical Records Should You Send First?
Core diabetes file
- Type 1, Type 2 or uncertain diagnosis
- Age and year diagnosed
- Latest HbA1c
- Current medication and insulin dose
- CGM report if available
- C-peptide and autoantibodies if relevant
Complications and your China goal
- Kidney function / urine albumin
- Cardiovascular history
- Eye / retinopathy reports
- Foot ulcer / vascular history
- Previous hospitalizations or surgery
- Trial ID, hospital name or stem-cell offer if you already found one
How the China Diabetes Case-Review Process Works
Send the medical file
We identify the diabetes type, current treatment, complications and the reason you are considering China.
Choose the right pathway
Routine specialist care, complications, metabolic treatment, hospital second opinion, or a research/trial inquiry.
Contact a relevant centre
Where appropriate, we ask whether the hospital or study team will review an overseas case and what additional information is required.
Plan after acceptance
Expected costs, stay length, invitation/visa and travel planning come after a realistic medical route has been confirmed.
Routing is not a clinical decision.
ParkMega can organize the records and identify whether the question belongs to standard hospital care, an
evidence-verification route or a registered clinical trial. The hospital or study team remains responsible for
diagnosis, acceptance, treatment planning and any trial-eligibility decision.
Send Your Diabetes Records Before Choosing a Hospital or Treatment Package
Tell us whether the case is Type 1 or Type 2, what treatment you use now, your latest HbA1c and what you want from China. If you already found a hospital, clinical trial or stem-cell offer, send that too.
✓ No obligation to book
✓ No cure guarantee
✓ Hospital/trial route checked before travel
Frequently Asked Questions
Direct answers to the main questions international patients ask about diabetes treatment in China.
Did China cure diabetes?
No universal cure has been established. Chinese researchers have reported important experimental results, including 2024 Type 1 and Type 2 stem-cell-derived islet reports and a 2026 Type 1 report involving three recipients. These are early selected research experiences, not a routine cure available to every patient.
What is actually different about diabetes treatment in China?
The foundations of evidence-based diabetes care are similar to international standards. China can differ in access to particular tertiary hospitals, a China-approved Type 2 medicine such as dorzagliatin, large metabolic-disease programs and an active regenerative-medicine and clinical-trial pipeline. These differences matter only when they match a specific patient problem.
Is dorzagliatin a cure for Type 2 diabetes?
No. Dorzagliatin is a glucokinase-activating glucose-lowering medicine approved in China for adults with Type 2 diabetes. Clinical studies show it can improve glycemic control in selected patients, but it should not be presented as a permanent cure or as a reason to travel without a physician-led treatment plan.
What is the standard treatment for Type 1 diabetes in China?
Standard Type 1 diabetes care remains insulin-based and can include continuous glucose monitoring, insulin pumps or automated insulin-delivery systems, education and screening for complications. Experimental islet or immune-cell studies are a separate pathway.
Can Type 2 diabetes go into remission?
Yes, some people with Type 2 diabetes can achieve remission. International consensus uses remission rather than cure when HbA1c remains below 6.5% for at least three months without usual glucose-lowering medication. Remission is not guaranteed and diabetes can recur.
Are diabetes clinical trials in China open to foreigners?
Possibly, but a registry status of “Recruiting” does not prove international access. The study site must confirm medical eligibility, nationality or residency requirements, language, required time in China and whether overseas follow-up is possible.
What are the best diabetes hospitals in China?
There is no single best hospital for every case. PUMCH, Ruijin Hospital, West China Hospital, the National Clinical Research Center for Metabolic Diseases at Second Xiangya Hospital and Tianjin First Center Hospital can each be relevant for different clinical or research needs. The correct choice depends on the diabetes type, complications and treatment goal.
How much does diabetes treatment in China cost?
There is no single national package price. Cost depends on the hospital, tests, devices, complication care, admission, surgery or experimental pathway. International patients should request a written case-specific estimate from a named hospital after their records have been reviewed.
Is stem-cell therapy for diabetes available in China?
China has published diabetes cell-therapy research and registered clinical studies, but this does not mean there is a routine licensed stem-cell cure for Type 1 or Type 2 diabetes. Commercial packages should be checked against the exact cell product, hospital, protocol or trial ID before payment.
What records should I send for a diabetes treatment review in China?
Send your diabetes type, age, year diagnosed, latest HbA1c, current medication and insulin dose, CGM report if available, C-peptide and autoantibodies when relevant, major kidney, cardiovascular, eye or foot complications, and any hospital, trial ID or treatment offer you are considering.
What do Chinese doctors use to treat diabetes?
Routine care uses the same major evidence-based categories used internationally: insulin, glucose monitoring and automated delivery for Type 1 diabetes; and individualized glucose-lowering medication, weight management, complication prevention and sometimes metabolic surgery for Type 2 diabetes. China also has locally approved options such as dorzagliatin for Type 2 diabetes and Tzield for selected people with stage 2 Type 1 diabetes.
Is Tzield available in China for Type 1 diabetes?
China’s NMPA approved teplizumab (Tzield) in 2025 for adults and children aged 8 years and older with stage 2 autoimmune Type 1 diabetes to delay progression to stage 3. It is not a cure and is not an indication for people who already have established stage 3 Type 1 diabetes simply because they are insulin dependent.
What is the GIFT smart probiotic for diabetes?
GIFT is an engineered glucose-sensing probiotic developed by researchers at East China Normal University. The 2026 work is early synthetic-biology research designed to sense glucose and release glucose-lowering hormones. It should not be described as an approved diabetes medicine or a treatment that an international patient can currently book.
How much does it cost to get Type 2 diabetes cured in China?
There is no official “Type 2 diabetes cure” price because China does not have a routine universal cure package. Costs depend on the real medical route: outpatient endocrinology, complication treatment, metabolic surgery, a clinical trial or an experimental commercial offer. Use a hospital-specific estimate after records review rather than a single advertised cure price.
Evidence and Primary Sources
Evidence-use rule: patient questions and search demand can identify what needs an answer, but medical,
provider-access, price and trial-status claims must come from the appropriate current primary or registry source.
Trial recruitment, provider intake routes and prices should be rechecked when they are time-sensitive.
- American Diabetes Association — Standards of Care in Diabetes—2026. Current recommendations cover insulin, CGM/AID technology, individualized Type 2 pharmacotherapy, obesity treatment and metabolic surgery. ADA Standards of Care 2026.
- ADA-led international consensus — Type 2 diabetes remission. Remission is defined using HbA1c below 6.5% for at least three months without usual glucose-lowering pharmacotherapy. Consensus report.
- International Diabetes Federation — China. IDF reports a large national diabetes burden, reinforcing why China has extensive diabetes clinical and research infrastructure. IDF China profile.
- Dorzagliatin evidence and post-approval literature. Peer-reviewed reviews and clinical studies describe dorzagliatin as a glucokinase activator approved in China for adults with Type 2 diabetes, including monotherapy and add-on use with metformin. PubMed review.
- Wang S. et al., Cell (2024), PMID 39326417. First-in-human Type 1 diabetes report using autologous chemically induced pluripotent-stem-cell-derived islets. PubMed record.
- Wu J. et al., Cell Discovery (2024), PMID 38684699. Type 2 diabetes case using personalized stem-cell-derived islet tissue; important proof of concept, not evidence of routine commercial availability. PubMed record.
- Shi Y. et al., Lancet Diabetes & Endocrinology (2026), PMID 41765034. Report of autologous and allogeneic stem-cell-derived islet therapy in three recipients with Type 1 diabetes and complete loss of endogenous beta-cell function before transplantation. PubMed record.
- Sanofi — Tzield approval in China (2025). China’s NMPA approved teplizumab for adults and children aged 8 years and older with stage 2 autoimmune Type 1 diabetes to delay progression to stage 3. Sanofi approval notice.
- East China Normal University — GIFT glucose-sensing probiotic research (2026). The university describes an engineered oral-deliverable glucose-sensing and functional response probiotic platform for metabolic therapy; this is research evidence, not a current patient-access claim. ECNU research summary.
- International Diabetes Federation — Beijing Ruijing Diabetes Hospital. IDF lists the hospital as a Centre of Excellence focused on diabetes treatment, complications and long-term management. IDF Centre of Excellence profile.
- Parkmega China Diabetes Clinical Trial Tracker. Current study IDs, sites, status freshness and foreign-patient-access caveats are maintained on a separate page so this hub does not hard-code rapidly changing recruitment information. Diabetes Clinical Trials in China.
Evidence note: medical research, trial recruitment and international-patient access can change. A publication or registry record does not automatically mean a treatment is commercially available or suitable for a specific patient.
Medical note: This page is for medical-travel research and hospital matching. It is not medical advice and should not be used to stop insulin or change diabetes medication without the treating clinical team.
Start With the Medical File, Not With a “Cure” Advertisement
Send your records and the question you want answered. We’ll identify whether the next useful step is Type 1 or Type 2 specialist care, complication management, a hospital shortlist, a cost estimate or a specific clinical-trial inquiry.
Start a diabetes case review
Choose the question you need answered. We prepare a records checklist and a WhatsApp message. ParkMega does not diagnose, enroll, accept patients, or guarantee a price.